Plastically deformable implant
View Patent ↗The invention relates to a plastically deformable implant for inserting into bodily orifices of the human or animal body. Implants of this type are used, for example, in ophthalmology, in particular, as vitreous body or lens replacements and in dentistry, for example, for filling extraction cavities in jaw-bones. Known implants, however, are not suitable for long-term use. The invention aims to provide a deformable plastic implant which also has a long-term application. This is achieved by the fact that the implant consists of a gel which is not sealed, containing fluorocarbon and which is directly introduced into the natural, or artificially created bodily orifice.
1. A plastically deformable implant for insertion into bodily orifices of a human or animal body, the implant formed by a gel which is not sealed and is directly introduced into a natural or artificially created bodily opening, with the gel having a polyaphron structure and comprising a fluorocarbon selected from the group consisting of perfluorophenanthrene, C 6 F 13 C 8 H 17 and (C 6 F 13 C 2 H 4 ) 3 , further comprising water, and a minimum of one fluorinated surface-active agent of the general formula R F -F pol , wherein:
R F stands for linear or branched perfluoroalkyl groups with more than 5 carbon atoms;
R pol stands for a polar hydrocarbon residue with a minimum of one functional group which is selected from the group consisting of CO—NH(R), CO—N(R) 2 , COO—, COOR, SO 3 —, SO 2 N(R) 2 , CH 2 —O—R, PO 2 H, and PO 3 H (R=alkyl); and
the surface-active agent has a molecular weight of >400 g/mol, a surface tension in aqueous solution of <30 mN/m, an interfacial tension in aqueous solution with respect to the fluorocarbon of <25 mN/m, and a concentration of <0.3%.
2. The implant of claim 1 wherein the fluorinated surface-active agent is selected from the group consisting of perfluoroalkyl ethanol oxethylate, perfluorooctanoic acid tetraethyl piperazinium salt, perfluorooctanoic acid N-methyl-D-glucamide, perfluorooctanoic acid diethanolamide, tetramethyl ammonium salt of perfluorooctanoic acid, perfluorooctanoic acid amidotrimethyl ammonium iodide, perfluorodecanoic acid N-(2-hydroxyethyl)-D-glucamide and perfluorooctanoic acid N-(2-hydroxyethyl)-D-glucamide.
3. The implant of claim 1 wherein the gel has a viscosity to density ratio greater than 0.1 Pa cm 3 /g and lower than 3 Pa cm 3 /g.
4. The implant of claim 3 wherein the ratio is lower than 1 Pa cm 3 /g.
5. The implant of claim 1 wherein after liquefaction the gel structure is reversible and can be completely restored.
6. The implant of claim 1 wherein the implant is an ophthalmologic implant.
7. The implant of claim 6 wherein the implant is a vitreous body or lens replacement.
8. The implant of claim 7 wherein the implant is permeable by water-soluble and ionic compounds and has a refractive index in a range from 1.334 to 1.338 and has a specific weight greater than 1.05 g/cm 3 .
9. The implant of claim 1 wherein the implant is a dental implant.
10. The implant of claim 9 wherein the implant is configured and dimensioned for filling extraction cavities in the jaw bone.
11. The implant of claim 1 wherein the implant is a tissue expander.
12. A method of treating tissue comprising the steps of inserting an implant formed in accordance with claim 1 into a bodily orifice located proximal to tissue to be treated, and treating the tissue to be treated with an oxygen therapy.
13. A method for treating a human or animal body comprising forming an implant as defined in claim 1 , and implanting said implant into a bodily orifice of a human or animal.
14. A method for treating a human or animal eye in a cataract operation comprising opening the capsular sac and removing the cloudy natural lens, injecting an implant as defined in claim 1 , ensuring that the entire capsular sac is completely filled with it; wherein the implant takes over the complete function of the natural lens.
15. A method of manufacture of an implant as defined in claim 1 , comprising preparing a mixture of 99% of the ultra-purified fluorocarbon, 0.9% isotonic physiological saline solution and 0.1% of the fluorinated surfactant with the use of ultrasound, adding a conventionally prepared polyaphron gel in a volume concentration of less than 30% slowly to the said mixture, until the entire mixture solidifies to form a gel.
16. The method of claim 15 , wherein the so-formed gel is either degassed or centrifuged.